17:25 , Aug 17, 2018 |  BC Week In Review  |  Company News

Astellas acquires ophthalmic company Quethera

Astellas Pharma Inc. (Tokyo:4503) acquired ophthalmic gene therapy company Quethera Ltd. (Cambridge, U.K.) for up to £85 million ($110.3 million). "This acquisition is a strategic fit as Astellas has prioritized ophthalmology as a new focus area...
16:06 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest a TrkB-agonizing BDNF peptide could help treat demyelination diseases. In a mouse model of CNS demyelination, intracerebroventricular infusion of a previously reported tricyclic BDNF peptide agonist of TrkB (EC50 = 11...
21:27 , Aug 10, 2018 |  BC Extra  |  Company News

Astellas acquires ophthalmic company Quethera

Astellas Pharma Inc. (Tokyo:4503) acquired ophthalmic gene therapy company Quethera Ltd. (Cambridge, U.K.) for up to £85 million ($110.3 million). "This acquisition is a strategic fit as Astellas has prioritized ophthalmology as a new focus area...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
01:45 , Jun 20, 2018 |  BC Extra  |  Preclinical News

Antibody selection method improves on phage display

A team at The Scripps Research Institute has developed a method to screen for functional antibodies that improves on standard phage display and incorporates functionality testing in one step. Principal investigator Richard Lerner told BioCentury the...
01:43 , Jun 9, 2018 |  BioCentury  |  Product Development

Past not prologue

Loxo Oncology Inc.’s two-year streak of stunning data at ASCO appears to be the result of good decisions on the back of a healthy dose of luck. But it will be a tall order to...
01:30 , Jun 2, 2018 |  BioCentury  |  Product Development

ASCO: Pushing precision’s evolution

As the list of targeted therapies gaining approval grows, encompassing an increasingly broad spectrum of cancers, this year’s ASCO meeting aims to educate clinicians about how to determine which drugs are best in class for...
19:16 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Priority review for Loxo's larotrectinib in tissue-agnostic indication

FDA accepted and granted Priority Review to an NDA for larotrectinib (LOXO-101) from Loxo Oncology Inc. (NASDAQ:LOXO) to treat locally advanced or metastatic solid tumors with neurotrophic tyrosine kinase receptor (Trk) fusion proteins, regardless of...
14:43 , May 29, 2018 |  BC Extra  |  Company News

Priority Review for Loxo's larotrectinib in tissue-agnostic indication

FDA accepted and granted Priority Review to an NDA for larotrectinib (LOXO-101) from Loxo Oncology Inc. (NASDAQ:LOXO) to treat locally advanced or metastatic solid tumors with neurotrophic tyrosine kinase receptor (Trk) fusion proteins, regardless of...
22:56 , May 22, 2018 |  BC Extra  |  Tools & Techniques

Trinity identifies hurdles for tissue-agnostic therapies

While the use of basket trials to test therapies in tissue agnostic, biomarker-based cancer indications is increasing, the long-term implications rely on a handful of factors, many of which may affect postmarket uptake of agents...